NASDAQ:ARAV ARAVIVE (ARAV) Stock Price, News & Analysis $0.04 0.00 (0.00%) As of 09/11/2025 Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsSEC FilingsSustainabilityTrendsBuy This Stock About ARAVIVE Stock (NASDAQ:ARAV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARAVIVE alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0452-Week Range$0.04▼$2.46VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aravive, Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative therapies that address mechanisms of tumor progression and treatment resistance. The company’s lead product candidate, AVB-500, is a high-affinity soluble receptor decoy designed to neutralize growth arrest-specific 6 (Gas6) and inhibit signaling through the Axl receptor tyrosine kinase. By targeting the Gas6/Axl pathway, Aravive aims to enhance the effectiveness of existing therapies and overcome resistance in oncology indications. AVB-500 is currently being evaluated in multiple Phase 2 clinical studies, including trials in platinum-resistant ovarian cancer and metastatic renal cell carcinoma, where it is administered in combination with standard-of-care treatments. In addition to its oncology programs, Aravive is exploring the role of Gas6/Axl signaling in fibrotic diseases, leveraging translational biomarkers and strategic collaborations to advance its preclinical candidates. The company’s development strategy emphasizes rigorous clinical design and partnerships to expedite the path to potential regulatory approval. Founded in 2015 and headquartered in Houston, Texas, Aravive operates clinical trial sites across North America and Europe. The company is led by Chief Executive Officer R. Joseph Eustace, whose experience in oncology drug development is complemented by a leadership team with deep expertise in translational science, clinical operations and regulatory affairs. Together, Aravive’s management is dedicated to translating novel scientific insights into therapeutic solutions for patients with high unmet needs.AI Generated. May Contain Errors. Read More Receive ARAV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ARAVIVE and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARAV Stock News HeadlinesOut-of-state companies win grants for trials at Houston's MD Anderson Cancer CenterNovember 27, 2024 | bizjournals.comAdial Pharmaceuticals Appoints Vinay Shah To Succeed Joseph Truluck As CFONovember 5, 2024 | markets.businessinsider.comYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.September 12 at 2:00 AM | Priority Gold (Ad)Global Automated Cell Culture Market to Exhibit Significant Growth at a CAGR of ~7% by 2030 | DelveInsightOctober 17, 2024 | finance.yahoo.comHouston-based health supplements co. to delist from Nasdaq, dissolveOctober 3, 2024 | bizjournals.comPharmaEssentia Appoints Robert Geller, M.D. as Head of Medical and Shawn Gibbs, J.D. as Head of LegalApril 23, 2024 | finance.yahoo.comDiabetic Kidney Disease Market to Witness Upsurge in Growth at a CAGR of ~6.5% by 2034 | DelveInsightApril 2, 2024 | finance.yahoo.comTelo Genomics Engages US Diagnostics Experts to Power Product Adoption in the USJanuary 30, 2024 | finance.yahoo.comSee More Headlines ARAV Stock Analysis - Frequently Asked Questions How have ARAV shares performed this year? ARAVIVE's stock was trading at $0.0401 at the beginning of the year. Since then, ARAV stock has increased by 0.0% and is now trading at $0.0401. How were ARAVIVE's earnings last quarter? ARAVIVE, INC (NASDAQ:ARAV) posted its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.07. The company had revenue of $2.41 million for the quarter, compared to analysts' expectations of $2.36 million. How do I buy shares of ARAVIVE? Shares of ARAV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ARAVIVE own? Based on aggregate information from My MarketBeat watchlists, some other companies that ARAVIVE investors own include NVIDIA (NVDA), CymaBay Therapeutics (CBAY), Broadcom (AVGO), GE Aerospace (GE), Advanced Micro Devices (AMD), CrowdStrike (CRWD) and Meta Platforms (META). Company Calendar Last Earnings10/27/2021Today9/12/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARAV CIK1513818 Webwww.aravive.com Phone(936) 355-1910FaxN/AEmployees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$9.14 million Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNo Data BetaN/A Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ARAV) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredCollege grad makes $64,000 a monthNothing hurts like a missed opportunity... And with AI stocks like Nvidia, Palantir, and Oracle continuing...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARAVIVE, INC Please log in to your account or sign up in order to add this asset to your watchlist. Share ARAVIVE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.